KDL Biotech Key Ratios
NSE: KOPDRUGS | BSE: 532291
₹2.14
As on 16-Mar-2015IST
Market cap
₹5 Cr
Revenue (TTM)
₹26 Cr
P/E Ratio
--
P/B Ratio
-0.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -6.83 | -- | -- |
| EBIT | -1.67 | 5.00 | 5.99 | 16.40 | 2.89 |
| Net Profit | -2.94 | 12.72 | 11.98 | 17.11 | -3.83 |
| EPS | -2.94 | -- | 73.24 | 19.78 | -198.50 |
| Book Value | -- | -- | -41.02 | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-12 | Mar-11 |
| EBIT-Margin
| -- | -- | -- | -42.32 | -136.25 |
| Net Margin
| -- | -- | -6,396.85 | -63.22 | -223.86 |
| Return on equity
| -- | -- | -- | 0.00 | 0.00 |
| Return on Capital
| -- | -- | -- | -108.39 | -101.90 |
| Return on Assets
| -- | -- | -26.44 | -28.21 | -78.59 |
| Debt to Equity (x)
| -- | -- | 0.00 | -1.02 | -1.43 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
-108.39
|
-101.90
|
-15.27
|
-11.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
--
|
--
|
-55.12
|
-108.11
|
|
Peer Median
|
10.86
|
--
|
--
|
--
|
--
|
ROA
-26.44
Lower than Peers by 33.18
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
-26.44
|
-28.21
|
-78.59
|
-16.21
|
-16.41
|
|
Peer Median
|
6.74
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
-42.32
|
-136.25
|
-58.68
|
-28.80
|
|
Peer Median
|
12.69
|
--
|
--
|
--
|
--
|
Net Margin
-6,396.85
Lower than Peers by 6,405.71
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
-6,396.85
|
-63.22
|
-223.86
|
-42.27
|
-33.83
|
|
Peer Median
|
8.86
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
-29.64
|
-144.55
|
-11.63
|
-23.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
-6.83
|
-25.98
|
-32.49
|
-66.47
|
|
Peer Median
|
8.14
|
--
|
--
|
--
|
--
|
EBIT Growth
5.99
Lower than Peers by 11.26
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
5.99
|
71.06
|
-71.88
|
--
|
22.04
|
|
Peer Median
|
17.24
|
--
|
--
|
--
|
--
|
Net Profit Growth
11.98
Lower than Peers by 4.88
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
11.98
|
73.24
|
-278.13
|
19.51
|
-55.97
|
|
Peer Median
|
16.85
|
--
|
--
|
--
|
--
|
EPS Growth
--
--
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
73.24
|
-278.13
|
19.51
|
-8.78
|
|
Peer Median
|
10.60
|
--
|
--
|
--
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
-41.02
|
-287.73
|
-43.21
|
14,768.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.00
Lower than Peers by 0.04
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
0.00
|
-1.02
|
-1.43
|
2.57
|
1.63
|
|
Peer Median
|
0.04
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-1.63
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
-1.63
|
-0.87
|
-1.22
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.06
Lower than Peers by 1.66
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
0.06
|
0.06
|
0.06
|
0.73
|
1.84
|
|
Peer Median
|
1.72
|
--
|
--
|
--
|
--
|
Quick Ratio
0.04
Lower than Peers by 1.13
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
0.04
|
0.04
|
0.04
|
0.60
|
1.50
|
|
Peer Median
|
1.17
|
--
|
--
|
--
|
--
|
Interest Coverage
-1.62
Lower than Peers by 9.49
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
-1.62
|
-1.54
|
-7.40
|
-4.69
|
-1.04
|
|
Peer Median
|
7.86
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
0.06
|
1.04
|
0.18
|
1.83
|
|
Peer Median
|
25.79
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
0.45
|
0.35
|
0.38
|
0.47
|
|
Peer Median
|
0.67
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
2.08
|
2.29
|
5.11
|
71.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
34.92
|
38.80
|
39.94
|
105.73
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
425.93
|
647.98
|
354.16
|
343.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
-388.93
|
-606.89
|
-309.11
|
-165.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
39.90
|
--
|
--
|
--
|
--
|
Price / Book Value
-0.05
Lower than Peers by 4.28
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
-0.05
|
-0.15
|
-0.31
|
1.33
|
0.71
|
|
Peer Median
|
4.23
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.10
|
--
|
--
|
--
|
--
|
EV/EBITDA
-34.23
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
-34.23
|
-52.39
|
-4.53
|
-10.46
|
-23.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
5
Lower than Peers by 7,607
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-12
|
Mar-11
|
Mar-10
|
Sep-08
|
|---|---|---|---|---|---|
|
KDL Biotech
|
5
|
9
|
13
|
30
|
28
|
|
Peer Median
|
7,613
|
--
|
--
|
--
|
--
|